AIDS 2026 | Tembeka Sineke: A Randomized Trial Exploring Integration of U=U Interventions into Standardized HIV Care for Adolescents in South Africa

AIDS 2026 | Tembeka Sineke: A Randomized Trial Exploring Integration of U=U Interventions into Standardized HIV Care for Adolescents in South Africa

The 2026 International AIDS Conference (AIDS 2026) was held in Rio de Janeiro, Brazil. HIV care for adolescents and the rollout of the Undetectable = Untransmittable (U=U) framework emerged as key discussion priorities at the conference. Young populations across sub-Saharan Africa bear a dual burden of HIV infection and pervasive social stigma. Integrating U=U interventions into routine clinical care serves as a critical pathway to improve their disease literacy, psychological wellbeing, and reduce high-risk sexual behaviours.
AIDS 2026 | Professor McMahon: Exploring the Clinical Potential of Half-Yearly Long-Acting Triple Regimens for HIV Treatment

AIDS 2026 | Professor McMahon: Exploring the Clinical Potential of Half-Yearly Long-Acting Triple Regimens for HIV Treatment

The 2026 International AIDS Conference (AIDS 2026) was successfully held in Rio de Janeiro, Brazil. The conference covered multi-dimensional topics including HIV prevention, diagnosis and treatment, and long-term disease management, bringing together scholars from the global infectious disease field for academic exchanges. Professor James McMahon from the Alfred Hospital and Monash University, Australia presented data from a 104-week Phase II clinical trial at the conference, focusing on evaluating the efficacy and safety of a half-yearly long-acting triple regimen combining lenacapavir, teropavimab and zinlirvimab. Long-acting administration represents a key developmental direction for current HIV therapy, drastically alleviating the daily pill-taking burden on patients and offering new insights for optimized long-term disease management. Infectious Disease Frontier conducted an exclusive interview with Professor McMahon to discuss the sustained viral suppression effects, tolerability profiles and target patient populations of this innovative long-acting triple regimen based on core primary clinical trial data, for reference by frontline clinical practitioners.
Professor Xuewen Jiang: Deepening MDT Collaboration to Advance Standardized Diagnosis and Treatment in Urologic Oncology

Professor Xuewen Jiang: Deepening MDT Collaboration to Advance Standardized Diagnosis and Treatment in Urologic Oncology

As diagnostic concepts and treatment strategies for urologic malignancies continue to evolve, clinical decision-making is shifting from relatively specialized, single-discipline treatment toward multidisciplinary, comprehensive management throughout the disease course. Multidisciplinary team (MDT) care integrates expertise from surgery, medical oncology, radiation oncology, radiology, pathology, and other specialties to develop more standardized, precise, and individualized treatment strategies for patients with complex and challenging disease. It has therefore become an important pathway for improving the quality of urologic oncology care. Oncology Frontier · UroStream invited Professor Xuewen Jiang of Qilu Hospital of Shandong University for an exclusive interview to share his experience with MDT practice in urologic oncology and discuss future directions for optimizing and expanding the model.
Professor Yanbo Wang: Strengthening End-to-End Quality Control and Data Governance to Build a High-Quality Clinical Research System in Urology

Professor Yanbo Wang: Strengthening End-to-End Quality Control and Data Governance to Build a High-Quality Clinical Research System in Urology

High-quality clinical research is an essential foundation for advancing medicine and improving patient outcomes. In urology, establishing robust top-level research design and end-to-end quality control, transforming large volumes of clinical records into standardized and usable research data, and helping young physicians identify research opportunities amid demanding clinical workloads have become important priorities in disciplinary development. In this issue of Oncology Frontier · UroStream, Professor Yanbo Wang of the First Hospital of Jilin University discusses the full-process quality control of clinical research in urology, clinical database development and data governance, as well as pathways for young physicians to develop their research careers, sharing practical experience and insights into building a high-quality clinical research system.
Professor Xin Yao: Precision Medicine and Minimally Invasive Technologies Working Together to Advance Urologic Oncology Care

Professor Xin Yao: Precision Medicine and Minimally Invasive Technologies Working Together to Advance Urologic Oncology Care

With the rapid development of molecular imaging, artificial intelligence, multi-omics technologies, and robotic surgery, the management of urologic cancers is gradually evolving from relatively standardized treatment toward more precise, minimally invasive, and individualized whole-course care. Precision medicine can improve the accuracy of tumor identification, risk stratification, and treatment selection, while robotic-assisted surgery provides important technical support for meticulous dissection, organ preservation, and functional reconstruction. Oncology Frontier · UroStream invited Professor Xin Yao of Tianjin Medical University Cancer Institute and Hospital for an exclusive interview to discuss pathways toward precision diagnosis and treatment in urologic oncology, as well as the clinical value and future directions of robotic surgery.
Advancing Clinical Innovation and Shaping the Future of Urology — Professor Liqun Zhou on the Development of Clinical Research and the Training of Young Urologists

Advancing Clinical Innovation and Shaping the Future of Urology — Professor Liqun Zhou on the Development of Clinical Research and the Training of Young Urologists

The Third Yellow River Urology Congress and the 31st Academic Conference of the Shandong Medical Association on Urology were recently held successfully. The conference brought together numerous experts and scholars in urology from across China to discuss cutting-edge advances, innovations in clinical practice, talent development, and regional collaboration. Oncology Frontier · UroStream invited Professor Liqun Zhou of Peking University First Hospital to provide an in-depth analysis of how to advance high-quality clinical research in urology and support the professional development of young physicians.
 Professor Shaoxing Zhu: Achieving Deep Testosterone Suppression and Maximizing Patient Benefit — Individualized ADT-Based Treatment Strategies for Prostate Cancer

 Professor Shaoxing Zhu: Achieving Deep Testosterone Suppression and Maximizing Patient Benefit — Individualized ADT-Based Treatment Strategies for Prostate Cancer

In recent years, the incidence and mortality of prostate cancer in China have increased significantly, driven by socioeconomic development and population aging, resulting in a growing disease burden. Androgen deprivation therapy (ADT), whether used alone or in combination, remains a cornerstone of comprehensive prostate cancer management. With updates to the Chinese Expert Consensus on Testosterone Management in Prostate Cancer and the Expert Consensus on Comprehensive Management of Prostate Cancer, clinical recommendations have evolved beyond achieving castration-level testosterone (<50 ng/dL) toward deep testosterone suppression (<20 ng/dL) and rapid, sustained PSA control, which may provide patients with better outcomes. Against this background, Oncology Frontier invited Professor Shaoxing Zhu of Fujian Medical University Union Hospital to discuss the evidence supporting deep testosterone suppression, individualized perioperative treatment strategies, and approaches that balance treatment efficacy with quality of life, with the goal of further improving survival and quality of life among patients with prostate cancer in China.
When All Seems Lost? — Rethinking the Optimal Treatment Sequence for Comprehensive Management of Advanced Renal Cell Carcinoma

When All Seems Lost? — Rethinking the Optimal Treatment Sequence for Comprehensive Management of Advanced Renal Cell Carcinoma

With the advent of immune checkpoint inhibitors, advanced renal cell carcinoma (RCC) has gradually entered the “immunotherapy era.” Targeted therapy plus immunotherapy (IO+TKI) combinations are now recommended by major guidelines and have become part of the first-line treatment landscape for advanced RCC. Although head-to-head trials have unequivocally demonstrated the superiority of first-line IO+TKI combinations over TKI monotherapy, “superior” in the first line does not necessarily mean “optimal” across the entire treatment journey.
Professor Mo Zhang: Fine Risk Stratification and Multimodal Integration — Exploring Precision Diagnosis and Treatment for High-Risk and Locally Advanced Prostate Cancer

Professor Mo Zhang: Fine Risk Stratification and Multimodal Integration — Exploring Precision Diagnosis and Treatment for High-Risk and Locally Advanced Prostate Cancer

High-risk and locally advanced prostate cancer is characterized by substantial biological heterogeneity, with significant differences in recurrence risk, metastatic potential, and treatment response among patients, making it a major challenge in clinical practice. With the development of novel androgen receptor pathway inhibitors, PSMA PET/CT, multi-omics technologies, and artificial intelligence, overcoming the limitations of traditional risk stratification, accurately identifying patients at truly extremely high risk, and integrating local and systemic therapies to improve long-term outcomes have become important areas of research. Oncology Frontier · UroStream invited Professor Mo Zhang of the Department of Urology, First Hospital of China Medical University, for an in-depth interview on the institution's single-center experience, precision stratification strategies, and future research directions in high-risk and locally advanced prostate cancer.